4.4 Review

What we have to know about corticosteroids use during Sars-Cov-2 infection

期刊

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
卷 44, 期 4, 页码 693-701

出版社

SPRINGER
DOI: 10.1007/s40618-020-01384-5

关键词

Glucocorticoid treatment; COVID-19; SARS-CoV 2; Drug interference; Adrenal insufficiency; Steroids; Infection

向作者/读者索取更多资源

Glucocorticoids (GCs), when used in SARS-CoV-2 patients, can lead to symptoms of hypercortisolism or hypoadrenalism, impacting mortality risk. Additionally, coadministration of antiretroviral drugs and corticosteroids may enhance drug-drug interaction and impact HPA axis function, emphasizing the need for appropriate tapering of GC dose and awareness of potential interactions.
Purpose Glucocorticoids (GCs), alone or associated to other drugs, were widely used in the management of patients affected by severe acute respiratory syndrome caused by SARS-CoV-2 infection, during the recent COVID-19 outbreak. This review summarizes the available data on HPA axis impairment in GC-treated SARS-CoV-2 patients, focusing on the risk of adrenal insufficiency and on potential drug interactions during concomitant treatments. Methods Literature on the impact of GCs therapy on HPA axis and on the consequences of coadministration of GCs and other drugs in SARS-CoV-2 patients has been reviewed. Results GC treatment can cause symptoms of hypercortisolism, especially in patients with individual hypersensibility, or hypoadrenalism after drug withdrawal, due to hypothalamic-pituitary-adrenal (HPA) axis suppression, with consequences in terms of increased morbidity and mortality risk. On the other hand, in SARS-CoV-2-infected patient's cortisol secretion could be insufficient also due to critical illness-related corticosteroid insufficiency (CIRCI). In addition, in this clinical context, the co-administration of antiretroviral drugs and corticosteroids may trigger drug-drug interaction and enhance the exposure to the latter ones, metabolized through the CYP450 CYP3A pathway, severely impacting on HPA axis. Conclusion Physicians involved in the management of patients affected by COVID-19 should be aware of the need of an appropriate GC dose tapering, and of potential interaction of GCs with antiviral therapy and drugs used to treat associated co-morbidities.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据